Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
In response to a coronavirus infection, the body's immune system mounts an inflammatory response against the virus. However, sometimes this inflammatory response is so sudden and strong that it becomes fatal.
Dr. Donald Weaver, a Senior Scientist and Director of UHN's Krembil Research Institute, recently showed in a pre-clinical study that furosemide, a small-molecule drug, has the potential to treat COVID-19 by reducing the harmful inflammation caused by the infection.
Furosemide is a diuretic commonly prescribed to treat high blood pressure, fluid build-up in the lungs and chronic kidney disease. It can be administered orally, intravenously, and by inhalation. It is also safe, readily available and part of the World Health Organization's Essential Medicines List.
It takes many years to bring a new drug to market. To accelerate the development of treatments for COVID-19, Dr. Weaver's team had turned to the strategy of repurposing existing drugs.
Searching through a library of 1,136 small molecules produced by the body, the research team found one molecule with significant anti-inflammatory potential known as 3-hydroxyanthranilic acid (3-HAA). They then looked for approved drugs that are similar in structure to 3-HAA.
Of the few candidates that were shortlisted, furosemide was the most promising. Cell culture studies revealed that furosemide inhibited the production of pro-inflammatory molecules and promoted the production anti-inflammatory molecules.
"Our pre-clinical study suggests that furosemide may be a candidate for repurposing as an inhaled therapy against COVID-19," says Dr. Weaver.
"Furosemide has been shown to reduce bronchial inflammation associated with asthma in previous clinical studies. We are currently pursuing a clinical study to assess whether it can reduce the severity of COVID-19 infection."
This work was supported by the Canada Research Chair Program and the Toronto General & Western Hospital Foundation. Dr.
Weaver holds a Tier 1 Canada Research Chair in Drug Design for Protein Misfolding Disorders.
Read more on the study.